Atoltivimab/Maftivimab/Odesivimab

N/A

Report date: 2023/04/21 17:46:59

First In Class

Base Information

Drug NameAtoltivimab/Maftivimab/Odesivimab

Drug Alias NameREGN 3470/3471/Maftivimab - Regeneron PharmaceuticalsEbola virus antibody - Regeneron PharmaceuticalsAtoltivimab/maftivimab/odesivimab-ebgnInmazebREGN 3470/3471/3479 +[13]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionEnvelope glycoprotein inhibitors

TargetsEnvelope glycoprotein

Therapy Area/IndicationsHemorrhagic Fever, Ebola

Global Approved IndicationsHemorrhagic Fever, Ebola

Approved Indications in ChinaN/A

Original Approved Country/TerritoryUnited States

Original Approved Date2020/10/14

Country/TerritoryUnited States

CombinationsYes Maftivimab Atoltivimab

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesRegeneron Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesRegeneron Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsHemorrhagic Fever, Ebola

Inactive IndicationsN/A

Other Information

ATC CodeL01XC